Coventry, United Kingdom, 19^th July 2021 – NanoSyrinx, a biotech company developing a new cell engineering tool for novel targeted therapeutic modalities, has raised a further £6.2m of seed financing, co-led by incoming Octopus Ventures and existing investor M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck KGaA. Previous investors BioCity and the UK Innovation & Science Seed Fund (UKI2S) joined the funding round along with experienced deeptech investor IQ Capital and Jonathan Milner. The round was significantly oversubscribed with high demand both from existing and from new investors.

Dr James Lapworth, Warwick Innovations, who has worked closely with the founding team since 2016 to develop the commercialisation strategy for the technology, said: “This latest investment into NanoSyrinx is a huge vote of confidence in the technology and in the team. It recognises not only the potential impact that nanosyringes could have as advanced medicines but also the entrepreneurial talent emerging from our researcher community.”

Nanosyrinx Funding Press Release

For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: j.lapworth@warwick.ac.uk

The University of Warwick spin-out company, CryoLogyx, has been awarded £300k from InnovateUK to develop innovate cryopreservation agents with applications in the diagnostic, medicines discovery and cell-based therapy markets.

For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: j.lapworth@warwick.ac.uk, tel: + 44 (0)2476 575481

Researchers in the UK and the United States have succeeded in ‘fine tuning’ a new thermoplastic biomaterial to enable both the rate at which it degrades in the body and its mechanical properties to be controlled independently.

For commercial enquiries contact Dr James Lapworth, Warwick Innovations, email: j.lapworth@warwick.ac.uk, tel: + 44 (0)2476 575481

NanoSyrinx announces the appointment of Dr Jane Dancer to its Board as Non-Executive Director.

NanoSyrinx, an emerging biotechnology company developing new therapeutic modalities for Cell & Gene editing, announced the closing of a Pre-Seed financing led by M Ventures, the corporate venture capital arm of Merck. BioCity (Nottingham, United Kingdom) and UK Innovation & Science Seed Fund also participated in the financing.

New study published on rapid test for Coronavirus being developed by University of Warwick demonstrates detection using a model virus rather than just proteins. The diagnostic tool will function without any need for training or complex infrastructure, looking like a ‘pregnancy test’. The team are seeking philanthropic or investment partners to develop and take forward this new technology

The Universities of Birmingham and Warwick have created a new spinout company, 4D Medicine Ltd, to commercialise a new class of materials – liquid resins that can be printed into solid 3D scaffolds to help patients recover from major medical procedures more quickly.

The work being done at University of Warwick, in collaboration with Iceni Diagnostics, around developing a new approach to rapid coronavirus diagnostics has been featured on the BBC. On Thursday 25 June, BBC Midlands interviewed Professor Gibson and members of his team - a feature on this can be read on the BBC News web pages. You can also see the news report video here.

Coronavirus diagnostics currently require centralised facilities and collection/distribution of swabs and results are ‘next day’. A new diagnostic tool being developed by the University of Warwick and its partner Iceni Diagnostics may allow on-the-spot detection of Coronavirus infection, without facilities using a simple disposal device.

Humane Technologies Limited (HTL) has announced that it has successfully developed a prototype for the next generation of its microbial growth measurement device, the MicrobeMeter.